Newswise — March 13, 2020 – As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there’s reassuring evidence that children have fewer symptoms and less severe disease. That’s among the insights provided by an expert review in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Like previous epidemic coronaviruses, “SARS-CoV-2 [seems] to cause fewer symptoms and less severe disease in children compared with adults,” according to the review by Petra Zimmerman, MD, PhD, of the University of Fribourg, Switzerland and Nigel Curtis, FRCPCH, PhD, of University of Melbourne and Murdoch Children’s Research Institute at the Royal Children’s Hospital, Australia. They summarize available evidence on coronavirus infections in children, including COVID-19.
“There is some suggestion that children are just as likely as adults to become infected with the virus but are less likely to be unwell or develop severe symptoms,” Drs. Zimmerman and Curtis write. “However, the importance of children in transmitting the virus remains uncertain.”
The Evidence on SARS-CoV-2 – Focusing on Risks to Children
Coronaviruses are a large family of viruses that can cause infection and disease in animals. “Coronaviruses are capable of rapid mutation and recombination, leading to novel coronaviruses that can spread from animals to humans,” Drs. Zimmerman and Curtis write. There are four coronaviruses that circulate in humans, mostly causing respiratory and gastrointestinal symptoms – ranging from the common cold to severe disease.
Over the past two decades, there have been three major disease outbreaks due to novel coronaviruses: SARS-CoV in 2002, MERS-CoV in 2012, and now SARS-CoV-2 in 2019. Arising in the Chinese city of Wuhan, SARS-Cov-2 spread rapidly around the world and has been declared a pandemic by the World Health Organization. “The term COVID-19 is used for the clinical disease caused by SARS-CoV-2,” according to the authors. Transmission of SARS-CoV-2 appears similar to that of the related SARS and MERS coronaviruses, but with a lower fatality rate. SARS-CoV-2 can still cause serious and life-threatening infections – particularly in older people and those with pre-existing health conditions.
What are the risks for children from SARS-CoV-2? It’s a pressing question for pediatric infectious disease specialists and concerned parents alike. Children appear to have milder clinical symptoms than adults and to be at substantially lower risk of severe disease – which was also true in the SARS and MERS epidemics.
In Chinese data from February 2020, children and adolescents accounted for only two percent of SARS-CoV-2 hospitalizations, Drs. Zimmerman and Curtis write. However, as children are less frequently symptomatic and have less severe symptoms they are less often tested, which might lead to an underestimate of the true numbers infected. Also, children are less frequently exposed to the main sources of transmission.
Again based on Chinese data, “Most infected children recover one to two weeks after the onset of symptoms, and no deaths had been reported by February 2020,” the researchers add. Most reported infections with SARS-CoV-2 have occurred in children with a documented household contact. Children with COVID-19 may be more likely to develop gastrointestinal symptoms.
The experts also review the diagnostic findings (laboratory tests and imaging studies) of children with COVID-19 laboratory and imaging findings in children. Whole genome sequencing approaches have enabled rapid development of molecular diagnostic tests for SARS-CoV-2. For now, treatment is supportive; no specific antiviral medications are available.
Several approaches are being considered for development of new drugs and vaccines – some targeting a “spike glycoprotein” involved in interactions between coronaviruses and cells. Until such treatment and preventive measures are available, the researchers emphasize the importance of the full range of strategies for controlling SARS-CoV-2 – as for the “highly effective global public health response” that led to containment of the SARS epidemic.
Click here to read “Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.”
About The Pediatric Infectious Disease Journal
The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research. The Pediatric Infectious Disease Journal is the official journal of the European Society for Paediatric Infectious Diseases
About The European Society for Paediatric Infectious Diseases
Now in its 36th year, The European Society for Paediatric Infectious Diseases (ESPID) forms the basis for European investigators interested in infectious diseases in children and infection prevention in childhood. The society is engaged in a number of activities including the organisation of multicentre trials, international exchange of infectious disease fellows, and an annual meeting. Membership includes subscription to The Pediatric Infectious Disease Journal® in addition to many other benefits.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
MEDIA CONTACTRegister for reporter access to contact details
The Pediatric Infectious Disease Journal